Amgen, Inc. vs Invesco S&P 500 Low Volatility ETF — how do they compare? Amgen, Inc. trades at $412.21 (market cap $224.14B), while Invesco S&P 500 Low Volatility ETF trades at $75.65. The key difference: Amgen, Inc. pays a 2.43% dividend while Invesco S&P 500 Low Volatility ETF pays none, and Amgen, Inc. is trading nearer its 52-week high, Invesco S&P 500 Low Volatility ETF nearer its low. Which is the better fit depends on your goals.
| AMGN | SPLV | |
|---|---|---|
Market Cap | $224.14B | — |
Sector | Health | — |
52-Week High | $417.20 | $77.97 |
52-Week Low | $271.18 | $70.30 |
Enterprise Value | $267.45B | — |
Dividend Yield | 2.43% | — |
Trailing returns across standard periods
Latest headlines on both assets
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the "index Provider") compiles, maintains and calculates the underlying index, which is designed to measure the performance of the 100 least volatile constituents of the S&P 500 ® Index over the past 12 months as determined by the index Provider.
Read more on SPLV →